Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Hyperammonemia Treatment Market Snapshot (2023 to 2033)

Expected to hold a valuation of US$ 1,318.05 Million in 2023, the hyperammonemia treatment market is forecast to register a CAGR of 4.77% during the 2023 to 2033 assessment period. By the end of the said decade, the market worth of hyperammonemia treatment is likely to touch US$ 2,100 Million.

A rising number of pipeline products for the treatment of hyperammonemia is anticipated to fuel the growth of the market in near future. For instance, on September 17, 2019, Kaleido Biosciences, a clinical-stage healthcare company, initiated a phase 2 clinical trial study to evaluate the efficacy and safety of KB195 in subjects with urea cycle disorder with severe symptoms. These studies and trials will help in driving the market growth of Hyperammonemia.

Additionally, the presence of better healthcare services and a growing number of innovative diagnostic approaches are likely to aid in the expansion of the market in the coming years. On the contrary, the impact of the novel coronavirus on this market has been negative as production was brought to a standstill, and so did the research and development procedure. Nevertheless, growing consumer awareness about such diseases and the rising support from various national governments in terms of reimbursement policies are likely to create new growth prospects in the coming years.

The Hyperammonemia treatment market is anticipated to offer lucrative opportunities in the near future due to the focus of major market players on inorganic growth strategies such as acquisitions, partnerships, and agreements to strengthen product portfolios and presence in the global market.

Report Attribute Details
Expected Market Value (2023) US$ 1,318.05 Million
Anticipated Forecast Value (2033) US$ 2,100 Million
Projected Growth Rate (2023 to 2033) CAGR 4.77%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Hyperammonemia Treatment Demand Analysis vs. Forecast 2023 to 2033

The hyperammonemia treatment market grossed a valuation of US$ 1,188.9 Million in 2022, trailing at a CAGR of 3.5%. Rising research and development activities by academic institutes in gene therapy for the treatment of Hyperammonemia are augmenting the growth.

Owing to these factors, the Hyperammonemia treatment market is projected to record a valuation of US$ 2,100 Million with a CAGR of 4.77% during the forecast period.

Which are Some Prominent Drivers of the Hyperammonemia treatment market?

High investments in Research and Development bolstering Market Growth

Research & development initiatives undertaken by research & academic institutes supported by pharmaceutical companies as well as governments are estimated to drive the global Hyperammonemia treatment market. Furthermore, the existence of well-established players, the rise in investments in research and development by pharmaceutical giants, and an association of pharmaceutical and biotech companies with research institutes will drive the global Hyperammonemia treatment market.

Additionally, research and development studies highlighting the genetic characterization of Hyperammonemia treatment will help market players align their product development, contributing to market expansion. In October 2021, Boehringer Ingelheim and Thoeris GmbH announced a collaboration and license agreement to investigate novel first-in-class therapies for patients with Hyperammonemia treatment (UCDs). Such partnership will help players leverage their expertise and expand their product offerings, thus propelling the market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Complications from long-term therapy to restrain product demand

The growing need for alternative diagnosis & treatment options, the absence of skilled personnel, and the dearth of reimbursement policies are some of the factors challenging market growth.

Moreover, due to long-term therapy, patients may suffer from some complications, like fussiness, sleepiness or sluggishness, low body temperature, vomiting, problems with posture, seizures, and others. Thus, such complications of long-term therapy are anticipated to hamper market growth over the forecast period. Additionally, the high cost of therapeutics is also expected to hinder market growth.

Region-Wise Insights

How is North America expected to perform in the Market for Hyperammonemia Treatment?

North American region is expected to hold a dominant position in the global Hyperammonemia treatment market over the forecast period, due to rising research and development by academic institutes in gene therapy for the treatment of Hyperammonemia. This region dominated the market in 2022 and is anticipated to retain its dominance in the coming years due to increasing research and development by academic institutes in gene therapy for the treatment of Hyperammonemia treatment. Also, owing to the well-developed health care system, rising awareness among the masses, a coalition of pharmaceutical and biotech companies with research institutes, and acceptance of the latest techniques in these nations are expected to fuel the Hyperammonemia treatment market growth till 2033.

The United States in this region is expected to hold a significant share of around 48% during the forecast period. There is a high burden of UCDs on the United States healthcare system, generating demand for its diagnostics and therapeutics, thus, driving the market growth. Furthermore, the Hyperammonemia treatment market is projected to expand rapidly in the next few years due to a well-developed healthcare system, appropriate reimbursement scenarios, and acceptance of the latest techniques in this region.

For instance, in March 2019, the University of Calgary Cumming School of Medicine (CSM) and Alberta Health Services (AHS) collaboratively initiated a clinical trial study on treatment of Hyperammonemia treatment with the help of gene therapy. The clinical trial study was conducted at Clinical Trials Unit (CTU) at the Foothills Medical Centre (FMC), a hospital in Canada. Thus, developments in gene therapy will strengthen the market growth.

How is South Asia expected to Shape Up in the Hyperammonemia Treatment Market?

The South Asian market is projected to register a steady revenue CAGR of 4.2% during the forecast period. There are various factors driving the market in South Asia for the treatment of hyperammonemia, including the presence of well-established companies, growth in Research and Development spending by pharmaceutical industry giants, and partnerships between pharmaceutical and biotech firms and research institutes.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights             

By Treatment, which Category is anticipated to Retain the Maximum Market Share?

Glycerol Phenylbutyrate-based Treatment is expected to Gain Maximum Momentum

Glycerol phenylbutyrate (Ravicti) is an adjunctive therapy for the chronic management of patients with Hyperammonemia. ‘Ravicti’ is the first licensed oral liquid of phenylbutyrate and shares the same mechanism of action and metabolic pathway as sodium phenylbutyrate.

Ravicti provides an alternative option in a formulation that may reduce the substantial treatment burden and unpleasant taste and odor associated with sodium phenylbutyrate which will propel the growth of this segment. This segment is expected to account for 35.5% segment share by end of the forecast period.

Which Distribution Channel will generate Maximum Hyperammonemia Treatment Drug Sales?

Hospital Pharmacies to be the Primary POC for availing Treatment Solutions

Future Market Insights expected the hospital pharmacy segments to hold the largest share of 48% in the hyperammonemia treatment market. This is mainly due to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the segment’s growth.

Start-ups in Hyperammonemia Treatment Market

  • Founded in 2006, Hyperion Therapeutics is a USA-based company that developed ‘Ravicti’, a drug for the treatment of both Hyperammonemia treatment (UCD) and hepatic encephalopathy (HE). The company was acquired by Horizon Pharma on March 30, 2015. It received a total funding of USD 148 million.
  • Founded in 2015, Archimedes is a US-based bioengineering start-up that is treating rare metabolic disease treatment paradigms through point-of-care diagnostic devices. The company is focused on Hyperammonemia treatment (UCD), phenylketonuria (PKU), and maple syrup-urine disease (MSUD). The company is supporting the development of precision medicine by providing physicians and caregivers the data they need to optimize medication and diet for patients with rare diseases. The company is based on a portfolio of patent-pending diagnostic technologies that enable the detection of aminoacidopathy disorders. This company is not funded yet.

Market Competition

The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are Bausch Health Companies, Inc, Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics, Ultragenyx Pharmaceutical Inc, Aeglea BioTherapeutics, Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd, Abbott Laboratories, Selecta Biosciences, Inc.

Some recent developments in this industry are:

  • In January 2021, Acer Therapeutics and Relief Therapeutics Holding AG entered into a collaboration and license agreement for the worldwide development and commercialization of acer-001, a sodium Phenylbutyrate drug conjugate for the treatment of urea cycle disorders.
  • In July 2022, Versantis AG revealed that the USA Food and Drug Administration (FDA) designated its major product candidate VS-01, an ammonia clearance enhancer, a rare pediatric disease designation for the treatment of Hyperammonemia.
  • In October 2021, according to Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics, the USA Food and Drug Administration (FDA) accepted the submission of the New Drug Application (NDA) for the drug ACER-001 (sodium phenylbutyrate) for the treatment of patients with Hyperammonemia disorder.
  • In January 2021, Recordati Rare Diseases Inc. received the USA Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1,318.05 Million
Market Value in 2033 US$ 2,100 Million
Growth Rate CAGR of 4.77% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Treatment
  • Route of administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Bausch Health Companies Inc.
  • Recordati Rare Diseases Inc.
  • Lucane Pharma SA
  • Acer Therapeutics
  • Ultragenyx Pharmaceutical Inc.
  • Aeglea BioTherapeutics
  • Arcturus Therapeutics Holdings Inc.
  • Orpharma Pty Ltd
  • Abbott Laboratories
  • Selecta Biosciences, Inc.
Customization Available Upon Request

Key Segments Profiled in the Hyperammonemia Treatment Market Industry Survey

By Treatment Type:

  • Amino Acid Supplements
  • Sodium Phenylbutyrate
  • Glycerol Phenylbutyrate
  • Sodium Benzoate
  • Others

By Route of Administration:

  • Oral
  • Injectable

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

How Big is the Global Hyperammonemia Treatment Market?

The global demand may generate US$ 1,318.05 million revenue in 2023.

What is the Advancement Rate for Adoption of Hyperammonemia Treatment Services?

Adoption of hyperammonemia treatment is poised to witness 4.77% CAGR through 2033.

Which Segment of Hyperammonemia Treatment Market Garners Higher Revenue?

The Ravicti segment is forecasted to have almost 35.5% of the market share by 2033.

What will be the Size of Hyperammonemia Treatment Market in the United States?

The country could retain its top position of capturing 48% of the global market.

What is the Scope of Growth for Hyperammonemia Treatment Market in South Asia?

It is currently the most lucrative market that could exhibit 4.2% CAGR through 2033.

Table of Content

1. Executive Summary | Hyperammonemia Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033

        5.3.1. Amino Acid Supplements

        5.3.2. Sodium Phenylbutyrate

        5.3.3. Glycerol Phenylbutyrate

        5.3.4. Sodium Benzoate

        5.3.5. Others

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Injectable

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East and Africa(MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Treatment Type

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment Type

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment Type

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment Type

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Treatment Type

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Treatment Type

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Treatment Type

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Treatment Type

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment Type

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of Middle East and Africa(MEA)

        15.2.2. By Treatment Type

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Treatment Type

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Treatment Type

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Treatment Type

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Treatment Type

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Treatment Type

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Treatment Type

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Treatment Type

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Treatment Type

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Treatment Type

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Treatment Type

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Treatment Type

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Treatment Type

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Treatment Type

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Treatment Type

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Treatment Type

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Treatment Type

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Treatment Type

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Treatment Type

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Treatment Type

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Treatment Type

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Treatment Type

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Treatment Type

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Treatment Type

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Bausch Health Companies, Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Recordati Rare Diseases Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Lucane Pharma SA

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Acer Therapeutics

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Ultragenyx Pharmaceutical Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Aeglea BioTherapeutics

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Arcturus Therapeutics Holdings Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Orpharma Pty Ltd.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Abbott Laboratories

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Selecta Biosciences, Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 17: Global Market Attractiveness by Treatment Type, 2023 to 2033

Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 37: North America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 77: Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 97: South Asia Market Attractiveness by Treatment Type, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 99: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 117: East Asia Market Attractiveness by Treatment Type, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 137: Oceania Market Attractiveness by Treatment Type, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033

Figure 139: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 157: MEA Market Attractiveness by Treatment Type, 2023 to 2033

Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 159: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Hypercalcemia Treatment Market

Published : September 2023

Testing Equipment

Blood Testing Equipment Market

Published : July 2023

Healthcare

Point Of Care Blood Testing Devices Market

Published : July 2022

Explore Healthcare Insights

View Reports

Hyperammonemia Treatment Market